NICE, France, May 27, 2016 -- ERI Scientific Beta, the smart beta index provider offshoot of EDHEC Risk Institute today announced a revolutionary "pay for what you get" approach to index pricing that will disrupt the traditional model of fixed fees on assets under management and enable investors to relate their fees directly to smart beta index performance.
As a non-profit academic institution, ERI Scientific Beta has always sought to provide the best research with favourable conditions to allow investors to invest in the best conditions possible. That is how ERI Scientific Beta made EDHEC Risk Institute's foundational pledge of transparency a reality. This transparency enabled the risks and robustness of strategies whose performance is essentially made up of simulated track records to be challenged. As such, all the data on ERI Scientific Beta's flagship Scientific Beta Multi-Beta Multi-Strategy indices, with the notable inclusion of historical composition, has been made available to investors without restriction. The new pricing proposition is part of ERI Scientific Beta's investor-friendly approach which has enabled it to attract more than USD 10bn in assets under replication for its smart beta indices in three years.
ERI Scientific Beta is offering this new pricing as an alternative to the traditional fixed fees on assets under management (AUM) of smart beta providers, whether asset managers or index providers. It involves a pure performance fees mandate that can be implemented at the request of an investor who only wishes to pay fees if the index has actually outperformed the reference cap-weighted index.
In practical terms, investors who choose this option from June 1, 2016, will pay zero fixed fees and will only pay variable fees if the flagship Scientific Beta Multi-Beta Multi-Strategy index outperforms the reference cap-weighted index.
This offer, with no fixed fees paid upfront and with the provider's remuneration being based on what the provider actually delivers to the investor, is the only one of its kind in the world.
Commenting on this new model, Noël Amenc, CEO of ERI Scientific Beta, said, "Our rationale for this mandate offer is that smart beta providers' claims on the quality and robustness of their strategies should materialise in their live performance. ERI Scientific Beta's initiative is intended to provide consistency between the smart beta provider's revenues and the quality of its offering. It is also testimony to the confidence we have in the performance of our smart beta indices, and notably our flagship Scientific Beta Multi-Beta Multi-Strategy indices, which have outperformed their cap-weighted equivalent by 4.51% on average since their live date."
As part of its policy of transferring know-how to the industry, EDHEC-Risk Institute has set up ERI Scientific Beta. ERI Scientific Beta is an original initiative which aims to favour the adoption of the latest advances in smart beta design and implementation by the whole investment industry. Its academic origin provides the foundation for its strategy: offer, in the best economic conditions possible, the smart beta solutions that are most proven scientifically with full transparency of both the methods and the associated risks.
ERI Scientific Beta, 1 George Street, #07-02, Singapore 049145. For further information, please contact: Séverine Cibelly, Tel.: +33 493 187 863, E-mail: [email protected], Web: www.scientificbeta.com.
Press_release_Pay_for_what_you_get.pdf http://hugin.info/157174/R/2016096/747686.pdf
HUG#2016096


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 



